Autopsy report · NCT02345746

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

“patient population”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Western Regional Medical Center

Sponsor type

University, hospital or other

Conditions

Metastatic Colorectal Cancer

Interventions

Oxaliplatin; Folinic Acid; 5-Fluorouracil

Participants

0

Trials that died the same way

• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
  “Lack of patient population” (82% match in meaning)
• POLA+BR for Relapsed or Refractory DLBCL
  “Lack of sufficient patient population” (78% match in meaning)
• RAPA-501-Allo Therapy of COVID-19-ARDS
  “Change in eligible patient population” (73% match in meaning)
• Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures
  “Limited number of patients” (72% match in meaning)
• Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
  “Insufficient study defined patient population” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.